Physical activity study for cardiac amyloidosis patients
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether a 12-week supervised exercise program is safe and helpful for people with cardiac amyloidosis and heart failure. It aims to see if regular exercise can improve how you feel and function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have heart failure (NYHA Class I, II, or III) from cardiac amyloidosis
- You are able to exercise and willing to attend 3 one-hour sessions per week for 12 weeks
- Your heart condition has been stable on treatment or you are being watched closely
- You can walk without help and have not had recent falls
- You do not need home oxygen for lung disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized exercise program for people with cardiac amyloidosis to see how it affects their heart and daily life. The goal is to help you feel better and stay active safely.
This study looks at how well people with cardiac amyloidosis can exercise and how that might relate to their long-term health. You'll do a supervised bike or treadmill test while your heart and lungs are monitored.
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
This trial is testing older adults with heart failure to see if a heart condition called cardiac amyloidosis (a buildup of abnormal protein in the heart) is present. If you are 80 or older, have been in the hospital for heart failure in the past year, and have a thickened heart wall, you may be able to join.
This study uses signals from a pacemaker or defibrillator to help detect a condition called cardiac amyloidosis, where abnormal proteins build up in the heart. It may help diagnose this condition earlier without extra tests.
This study looks at how cardiac amyloidosis shows up on heart imaging, especially ultrasound (echocardiography). It may help doctors better describe and track the condition using your exam and test results.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.